Skip to main content
Figure 3 | Cardiovascular Diabetology

Figure 3

From: The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

Figure 3

Empagliflozin exposure-response relationships for placebo-corrected QTcN (A) and heart rate (B) changes from baseline. Placebo-corrected changes from baseline versus plasma concentrations of empagliflozin for empagliflozin 25 mg and empagliflozin 200 mg treatment groups. HR, heart rate; QTcN, population heart rate-corrected QT interval. Data from the full analysis set.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840